AI/ML Innovations Inc. develops artificial intelligence and neural-network technology for digital health applications. The company’s platforms use signal processing and deep learning to convert biometric data into clinical insights, with recurring updates centered on ECG analysis, heart rate variability analytics, remote cardiac monitoring, and cardiovascular research support.
News for AIMLF also covers activity at its Neural Cloud Solutions subsidiary, including MaxYield™, CardioYield™, and Insight 360™ commercialization, reseller and distribution agreements, research-services collaborations, medical advisory board appointments, and capital-structure actions such as private placements, convertible debentures, warrants, options, and share issuances for debt settlement.
AI/ML Innovations (AIMLF) subsidiary NeuralCloud signed an agreement with Etisense to integrate MaxYield into animal-model electrocardiogram (ECG) analysis workflows. The October 27, 2026 agreement covers AI-powered labeling and analysis of ECG data captured through Etisense's LASA software.
The parties expect to start with representative ECG files, then proceed to technical integration and online licensing for ongoing customer use. Initial validation is free to Etisense, and further work requires its written approval. Work will begin with large-animal models; extension to mouse and rat models is intended following successful large-animal validation.
The agreement is non-exclusive, and NeuralCloud retains all MaxYield intellectual property rights. Etisense retains customer relationships, workflow delivery and final review. The collaboration focuses on preclinical research, not clinical or diagnostic use.
AI/ML Innovations (AIMLF) has amended its articles to require advance notice for certain shareholder nominations of directors, effective immediately. The rules exclude nominations made through a meeting request or shareholder proposal under the Business Corporations Act.
For annual meetings, notice generally must arrive 30 to 65 days before the meeting, with a separate deadline for meetings announced on shorter notice. The board may waive any requirement at its discretion. The amendments will cease to be effective unless approved, ratified and confirmed by a majority of votes cast at the next Annual and Special Meeting of Shareholders.
AI/ML Innovations (AIMLF) completed a share-for-debt issuance totaling CAD$387,203 to certain service providers for past services and outstanding indebtedness.
The company issued 7,744,062 common shares at a deemed price of CAD$0.05 per share. The shares carry a statutory hold period expiring on February 10, 2027. Company insiders expect to purchase, directly or indirectly, 4,900,001 of these shares, making the issuance a related-party transaction under Multilateral Instrument 61-101, which protects minority security holders in special transactions.
AI/ML Innovations (AIMLF) appointed Lynn Chapman as Chief Financial Officer, effective October 1, 2026, replacing Terence Lee in the role. Chapman is a Chartered Professional Accountant with more than 15 years of financial and managerial experience.
The company also entered into agreements with service providers proposing to issue 7,744,062 common shares at CAD$0.05 per share for past services and outstanding indebtedness. Issuance remains subject to Canadian Securities Exchange approval. Insiders expect to purchase, directly or indirectly, 4,900,001 of these shares, making the issuance a related-party transaction. The company is exempt from formal valuation and minority shareholder approval requirements under MI 61-101, based on its CSE listing and the related-party portion not exceeding 25% of its market capitalization under the instrument's valuation rules.
AI/ML Innovations (AIMLF), through its wholly owned subsidiary NeuralCloud, signed a binding commercial term sheet and service level agreement with VetMed Consultants. Dated September 25, 2026, the agreement establishes a phased evaluation of MaxYield ECG processing for preclinical cardiac safety work serving pharmaceutical sponsors and contract research organizations.
Technical validation will begin with anonymized ECG files across selected species and study formats. Following validation, the parties expect to pursue workflow integration and a VetMed-dedicated environment with privacy, security and quality controls. VetMed retains client relationships, clinical review and final scientific sign-off. MaxYield has not yet been third-party tested or validated for preclinical ECG data; production use depends on VetMed's validation and approval.
AI/ML Innovations (AIMLF) subsidiary NeuralCloud partnered with RKS Medical Technologies to pilot CardioYield software alongside myPatch Holter monitors. RKS Medical is expected to introduce clinics using or evaluating myPatch, while NeuralCloud would run the pilots, initially in Ontario. The planned evaluations would compare de-identified ECG recordings processed through clinics’ existing workflows and CardioYield.
CardioYield has not received Health Canada or FDA clearance and is not authorized for diagnostic use. Clinics’ existing systems and qualified healthcare professionals would remain responsible for official reports and care decisions. AIML also extended 44,189,076 existing share purchase warrants, exercisable at $0.15 per share, from November 2026 to corresponding dates in November 2029. The extension covers 19,688,461 warrants expiring November 1 and 24,500,615 expiring November 26.
AI/ML Innovations (AIMLF) launched Quantum Soma, a new project to develop a contactless quantum biosensing platform that combines Dynex Quantum Technologies’ NV-diamond quantum sensor with AIML’s MaxYield™ AI signal-intelligence engine.
Effective September 21, 2026, AIML entered a non-binding purchase order with Dynex for up to 2,000 Single Zone NV-diamond sensors at CHF 2,500 each, for a maximum value of CHF 5,000,000 if fully drawn, with no minimum purchase, deposits, development fees, or termination penalties. Dynex is expected to deliver a combined prototype in about nine months, focused initially on detecting cardiac magnetic signatures, with any future clinical or diagnostic use subject to regulatory clearance.
AI/ML Innovations (AIMLF) closed the second and final tranche of its non-brokered private placement, raising $365,000.
In this tranche, the company issued 7,300,000 units at $0.05 per unit, each unit consisting of one common share and one common share purchase warrant. Each whole warrant is exercisable at $0.15 per share for 60 months from the issuance date, subject to anti-dilution provisions in the warrant certificates. The company also issued 196,000 broker warrants to eligible finders, each exercisable at $0.15 per share for five years.
All securities issued in this tranche are subject to a statutory hold period expiring on January 15, 2027. The company notes that the securities are not registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States without registration or an available exemption. Completion of the offering remains subject to all applicable regulatory consents.
AI/ML Innovations (OTCQB:AIMLF) reported that its wholly owned subsidiary, NeuralCloud Solutions, has appointed former U.S. FDA lead reviewer Dr. Mehmet A. Kosoglu as Head of Regulatory. He brings more than 15 years of experience across medical devices, biotechnology, FDA regulations, Software as a Medical Device (SaMD), digital health, diagnostics, and combination products.
According to the company, Dr. Kosoglu will guide regulatory strategy for NeuralCloud’s AI-powered cardiac technologies, including MaxYield™ and CardioYield™, as the subsidiary advances ECG signal-processing platforms toward validation, regulatory engagement, and commercial deployment. The appointment follows NeuralCloud’s ISO 13485:2016 MDSAP certification, which established a quality management system for regulated medical device development and commercialization.
AI/ML Innovations (CSE:AIML, OTCQB:AIMLF, FSE:42FB) has closed the first tranche of its previously announced non-brokered private placement, issuing 16,385,000 units at $0.05 per unit for gross proceeds of $819,250. Each unit consists of one common share and one common share purchase warrant.
Each whole warrant is exercisable at $0.15 per share for 60 months from issuance, subject to anti-dilution provisions. The company also issued 936,950 broker warrants to eligible finders, each exercisable at $0.15 for five years. All securities from this tranche are subject to a statutory hold period expiring on December 27, 2026.